Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Type of Cancer
Skin and Soft Tissue

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA6141

To Learn More Call
201-510-0910